Drug intelligence / Profile preview

VTx-101

Development stage: Preclinical
Lead developer: Duke University
Modality: Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

VTx-101 (Veiled Uricase) is a polymer-conjugated recombinant uricase (urate oxidase) enzyme being developed by Veil Therapeutics for the treatment of chronic gout (including chronic refractory gout). The therapeutic utilizes the company's proprietary Veil Platform (PEGNEXT technology), which rearranges PEG-based polymers into small, discrete units with high-density, short side chains that adopt a bottlebrush structure. This polymer shield reduces the immunogenicity of the uricase enzyme, extending its half-life and stability while evading immune recognition. VTx-101 is currently in preclinical development.

Other names: Veiled Uricase

Beyond the preview

Go deeper on VTx-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTx-101.

Explore the full profile